{"id":"NCT02696785","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","officialTitle":"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-02","primaryCompletion":"2017-12-08","completion":"2018-10-17","firstPosted":"2016-03-02","resultsPosted":"2019-11-19","lastUpdate":"2019-11-19"},"enrollment":341,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Adalimumab","otherNames":[]}],"arms":[{"label":"Q2W Ixekizumab","type":"EXPERIMENTAL"},{"label":"Q4W Ixekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).","primaryOutcome":{"measure":"Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":18.4,"sd":null},{"arm":"Adalimumab","deltaMin":35.6,"sd":null},{"arm":"IXE80Q4W","deltaMin":48.1,"sd":null},{"arm":"IXE80Q2W","deltaMin":51.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":28,"countries":["United States","Czechia","Germany","Japan","Netherlands","South Korea","Taiwan"]},"refs":{"pmids":["40694276","39983751","39509838","39004432","38637464","36792107","36282526","35429281","35188180","34853086","34538257","31685553","31254223"],"seeAlso":["http://www.lillytrialguide.com/en-US/studies/axial-spondyloarthritis%20(ankylosing%20spondylitis)/RHBV#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Injection site reaction","Diarrhoea","Back pain"]}}